

Jay D Horton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6117586/publications.pdf>

Version: 2024-02-01

50
papers

26,299
citations

101384

36
h-index

205818

48
g-index

52
all docs

52
docs citations

52
times ranked

27971
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to Kunos et al. and Lotersztajn and Mallat. Journal of Clinical Investigation, 2022, 132, .	3.9	1
2	CB1Rs in VMH neurons regulate glucose homeostasis but not body weight. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E146-E155.	1.8	9
3	Decreased caveolae in AGPAT2 lacking adipocytes is independent of changes in cholesterol or sphingolipid levels: A whole cell and plasma membrane lipidomic analysis of adipogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166167.	1.8	5
4	Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD. Journal of Clinical Investigation, 2021, 131, .	3.9	23
5	The impact of endotrophin on the progression of chronic liver disease. Experimental and Molecular Medicine, 2020, 52, 1766-1776.	3.2	25
6	Delisting <i>STAP1</i>. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 847-849.	1.1	10
7	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	1.0	776
8	Intravascular triglyceride lipolysis becomes crystal clear. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1480-1482.	3.3	7
9	Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. Journal of Lipid Research, 2018, 59, 475-487.	2.0	148
10	Adipocyte Xbp1s overexpression drives uridine production and reduces obesity. Molecular Metabolism, 2018, 11, 1-17.	3.0	34
11	Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease. Molecular Metabolism, 2018, 14, 121-129.	3.0	35
12	Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1189-1194.	3.3	143
13	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	1.0	2,292
14	Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. Journal of Lipid Research, 2017, 58, 1661-1669.	2.0	41
15	An adipo-biliary-uridine axis that regulates energy homeostasis. Science, 2017, 355, .	6.0	90
16	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metabolism, 2017, 26, 394-406.e6.	7.2	265
17	A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. New England Journal of Medicine, 2017, 376, 41-51.	13.9	571
18	Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. ELife, 2017, 6, .	2.8	82

#	ARTICLE	IF	CITATIONS
19	AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. <i>Molecular Metabolism</i> , 2016, 5, 491-505.	3.0	36
20	CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. <i>Nature Communications</i> , 2016, 7, 10961.	5.8	165
21	Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2 ^{+/+} /âˆ™) or obese (ob/ob) mice. <i>Journal of Lipid Research</i> , 2016, 57, 616-630.	2.0	29
22	MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. <i>Nature Medicine</i> , 2015, 21, 1280-1289.	15.2	203
23	Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance. <i>Journal of Lipid Research</i> , 2014, 55, 2597-2605.	2.0	61
24	Acetate Dependence of Tumors. <i>Cell</i> , 2014, 159, 1591-1602.	13.5	524
25	An acetate switch regulates stress erythropoiesis. <i>Nature Medicine</i> , 2014, 20, 1018-1026.	15.2	62
26	Abstract 61: LXR Agonist Treatment of Nonhuman Primates Increases LDL Cholesterol due to Decreased Hepatic LDL Receptor Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	1.1	0
27	The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in Animals. <i>Cell Metabolism</i> , 2012, 15, 240-246.	7.2	263
28	Human Fatty Liver Disease: Old Questions and New Insights. <i>Science</i> , 2011, 332, 1519-1523.	6.0	1,780
29	Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. <i>Journal of Lipid Research</i> , 2009, 50, 412-423.	2.0	181
30	PCSK9: a convertase that coordinates LDL catabolism. <i>Journal of Lipid Research</i> , 2009, 50, S172-S177.	2.0	517
31	Unfolding Lipid Metabolism. <i>Science</i> , 2008, 320, 1433-1434.	6.0	11
32	Statins Induce Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9. <i>FASEB Journal</i> , 2008, 22, 1040.4.	0.2	0
33	Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. <i>Journal of Biological Chemistry</i> , 2007, 282, 18602-18612.	1.6	660
34	Molecular biology of PCSK9: its role in LDL metabolism. <i>Trends in Biochemical Sciences</i> , 2007, 32, 71-77.	3.7	512
35	Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. <i>Journal of Clinical Investigation</i> , 2006, 116, 2995-3005.	3.9	587
36	Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 5374-5379.	3.3	637

#	ARTICLE	IF	CITATIONS
37	Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver. <i>Journal of Biological Chemistry</i> , 2004, 279, 50630-50638.	1.6	442
38	Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. <i>Hepatology</i> , 2004, 40, 1387-1395.	3.6	3,250
39	Molecular mediators of hepatic steatosis and liver injury. <i>Journal of Clinical Investigation</i> , 2004, 114, 147-152.	3.9	1,571
40	Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. <i>Journal of Clinical Investigation</i> , 2004, 113, 1168-1175.	3.9	218
41	Molecular mediators of hepatic steatosis and liver injury. <i>Journal of Clinical Investigation</i> , 2004, 114, 147-152.	3.9	944
42	Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12027-12032.	3.3	1,233
43	Overexpression of Sterol Regulatory Element-binding Protein-1a in Mouse Adipose Tissue Produces Adipocyte Hypertrophy, Increased Fatty Acid Secretion, and Fatty Liver. <i>Journal of Biological Chemistry</i> , 2003, 278, 36652-36660.	1.6	195
44	Diminished Hepatic Response to Fasting/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1c. <i>Journal of Biological Chemistry</i> , 2002, 277, 9520-9528.	1.6	563
45	SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. <i>Journal of Clinical Investigation</i> , 2002, 109, 1125-1131.	3.9	3,528
46	SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. <i>Journal of Clinical Investigation</i> , 2002, 109, 1125-1131.	3.9	2,177
47	SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. <i>Genes and Development</i> , 2001, 15, 1206-1216.	2.7	279
48	Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus. <i>Journal of Biological Chemistry</i> , 1999, 274, 30028-30032.	1.6	616
49	Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. <i>Journal of Clinical Investigation</i> , 1999, 103, 1067-1076.	3.9	174
50	Nuclear Sterol Regulatory Element-binding Proteins Activate Genes Responsible for the Entire Program of Unsaturated Fatty Acid Biosynthesis in Transgenic Mouse Liver. <i>Journal of Biological Chemistry</i> , 1998, 273, 35299-35306.	1.6	320